Show simple item record

dc.contributor.authorFraser, Jess
dc.contributor.authorFardus‐Reid, Fahmina
dc.contributor.authorIrvine, Lucy
dc.contributor.authorElliss‐Brookes, Lucy; orcid: 0000-0003-1159-6607
dc.contributor.authorFern, Lorna; orcid: 0000-0003-4821-8466
dc.contributor.authorCameron, Alison L.
dc.contributor.authorPritchard‐Jones, Kathy; orcid: 0000-0002-2384-9475
dc.contributor.authorFeltbower, Richard G.
dc.contributor.authorShelton, Jon
dc.contributor.authorStiller, Charles
dc.contributor.authorMcCabe, Martin G.; orcid: 0000-0002-5138-0707; email: martin.mccabe@manchester.ac.uk
dc.date.accessioned2021-07-06T10:12:28Z
dc.date.available2021-07-06T10:12:28Z
dc.date.issued2021-07-06
dc.date.submitted2020-10-27
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625151/pbc.29204.pdf?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625151/pbc.29204.xml?sequence=3
dc.identifier.citationPediatric Blood & Cancer, page e29204
dc.identifier.urihttp://hdl.handle.net/10034/625151
dc.descriptionFrom Wiley via Jisc Publications Router
dc.descriptionHistory: received 2020-10-27, rev-recd 2021-06-04, accepted 2021-06-16, pub-electronic 2021-07-06
dc.descriptionArticle version: VoR
dc.descriptionPublication status: Published
dc.description.abstractAbstract: Background: Oral etoposide is commonly used in palliative treatment of childhood and young adult cancer without robust evidence. We describe a national, unselected cohort of young people in England treated with oral etoposide using routinely collected, population‐level data. Methods: Patients aged under 25 years at cancer diagnosis (1995–2017) with a treatment record of single‐agent oral etoposide in the Systemic AntiCancer Dataset (SACT, 2012–2018) were identified, linked to national cancer registry data using NHS number and followed to 5 January 2019. Overall survival (OS) was estimated for all tumours combined and by tumour group. A Cox model was applied accounting for age, sex, tumour type, prior and subsequent chemotherapy. Results: Total 115 patients were identified during the study period. Mean age was 11.8 years at cancer diagnosis and 15.5 years at treatment with oral etoposide. Median OS was 5.5 months from the start of etoposide; 13 patients survived beyond 2 years. Survival was shortest in patients with osteosarcoma (median survival 3.6 months) and longest in CNS embryonal tumours (15.5 months). Across the cohort, a median of one cycle (range one to nine) of etoposide was delivered. OS correlated significantly with tumour type and prior chemotherapy, but not with other variables. Conclusions: This report is the largest series to date of oral etoposide use in childhood and young adult cancer. Most patients treated in this real world setting died quickly. Despite decades of use, there are still no robust data demonstrating a clear benefit of oral etoposide for survival.
dc.languageen
dc.rightsLicence for VoR version of this article: http://creativecommons.org/licenses/by-nc/4.0/
dc.sourceissn: 1545-5009
dc.sourceissn: 1545-5017
dc.subjectONCOLOGY: RESEARCH ARTICLE
dc.subjectAYA
dc.subjectcancer
dc.subjectchildren
dc.subjectetoposide
dc.subjectpopulation
dc.subjectsurvival
dc.titleOral etoposide as a single agent in childhood and young adult cancer in England: Still a poorly evaluated palliative treatment
dc.typearticle
dc.date.updated2021-07-06T10:12:28Z
dc.date.accepted2021-06-16


Files in this item

Thumbnail
Name:
pbc.29204.pdf
Size:
578.9Kb
Format:
PDF
Thumbnail
Name:
pbc.29204.xml
Size:
10.63Kb
Format:
XML

This item appears in the following Collection(s)

Show simple item record